Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Revolution Medicines (RVMD)
NASDAQ:RVMD
Holding RVMD?
Track your performance easily
RVMD Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$23.38 - $62.40
Previous Close$57.85
Volume4.28M
Average Volume (3M)1.22M
Market Cap
$9.73B
Enterprise Value$8.27B
Total Cash (Recent Filing)$1.55B
Total Debt (Recent Filing)$86.71M
Price to Earnings (P/E)―
Beta1.65
Next Earnings
Mar 03, 2025EPS Estimate
-$1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.59
Shares Outstanding168,219,391
10 Day Avg. Volume1,421,669
30 Day Avg. Volume1,219,349
Standard Deviation0.17
R-Squared0.20
Alpha0.00433
Financial Highlights & Ratios
Price to Book (P/B)6.13
Price to Sales (P/S)12802.36
Price to Cash Flow (P/CF)-18.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue11.14K
Enterprise Value/Gross Profit714.05
Enterprise Value/Ebitda-15.42
Forecast
1Y Price Target
$68.18Price Target Upside31.62% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
Revolution Medicines News
Bulls Say, Bears Say
Bulls Say
Clinical OpportunitiesThere is potential for ongoing momentum in RVMD shares due to initial responses related to RMC-6236 and steady clinical execution with RMC-6291.
Financial PerformanceRVMD ended 3Q24 with $1.55B in cash and equivalents, with cash runway guidance remaining into 2027.
Strategic ProfileCurrent levels are seen as underappreciating the increasingly derisked RMC-6236-/+ RMC-6291 optionality in NSCLC and the company's overall heightened strategic profile within the targeted oncology arena.
Bears Say
Clinical Trial DelaysThe Phase III trial initiation for RMC-6236 monotherapy in second-line non-small-cell lung cancer (NSCLC) has been pushed to the first quarter of 2025 from the fourth quarter of 2024.
Market SkepticismInvestors have been largely dismissive of this program, due to prior negative experience with commercial sales of KRAS G12C inhibitors.
Safety ConcernsThe safety profile worsened on the margin from the prior update with higher rates of adverse events.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
RVMD FAQ
What was Revolution Medicines’s price range in the past 12 months?
Revolution Medicines lowest stock price was $23.38 and its highest was $62.40 in the past 12 months.
What is Revolution Medicines’s market cap?
Currently, no data Available
When is Revolution Medicines’s upcoming earnings report date?
Revolution Medicines’s upcoming earnings report date is Mar 03, 2025 which is in 76 days.
How were Revolution Medicines’s earnings last quarter?
Revolution Medicines released its earnings results on Nov 06, 2024. The company reported -$0.94 earnings per share for the quarter, missing the consensus estimate of -$0.893 by -$0.047.
Is Revolution Medicines overvalued?
According to Wall Street analysts Revolution Medicines’s price is currently Undervalued.
Does Revolution Medicines pay dividends?
Revolution Medicines does not currently pay dividends.
What is Revolution Medicines’s EPS estimate?
Revolution Medicines’s EPS estimate is -$1.
How many shares outstanding does Revolution Medicines have?
Revolution Medicines has 168,219,390 shares outstanding.
What happened to Revolution Medicines’s price movement after its last earnings report?
Revolution Medicines reported an EPS of -$0.94 in its last earnings report, missing expectations of -$0.893. Following the earnings report the stock price went down -0.539%.
Which hedge fund is a major shareholder of Revolution Medicines?
Among the largest hedge funds holding Revolution Medicines’s share is Farallon Capital Management, L.L.C.. It holds Revolution Medicines’s shares valued at 513M.
---
Revolution Medicines Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$68.18 (31.62% Upside)
$68.18 (31.62% Upside)
Blogger Sentiment
Bullish
RVMD Sentiment 66%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 1.5M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.2%
Last 30 Days ▼ 6.2%
Last 30 Days ▼ 6.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
157.56%
12-Months-Change
Fundamentals
Return on Equity
-47.18%
Trailing 12-Months
Asset Growth
79.12%
Trailing 12-Months
Company Description
Revolution Medicines
Revolution Medicines, Inc. is a clinical-stage precision oncology company focused on developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.
---
RVMD Earnings Call
Q3 2024
0:00 / 0:00
---
RVMD Stock 12 Month Forecast
Average Price Target
$68.18
▲(31.62% Upside)
Technical Analysis
Best Analysts Covering RVMD
1 Year
1 Year Success Rate
10/10 ratings generated profit
1 Year Average Return
+47.92%
assigned a buy rating 2 months ago
Copying Jay Olson's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +47.92% per trade.
---